Evidence map›Paper›PMID 34997990›Full record

ArticleUnited European gastroenterology journal2022

Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters.

Sabrina Sidali, Jean-Charles Nault

Registry-linked trialAbstract readEditorialComment
In one paragraph

Article in United European gastroenterology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06594744 (A Randomized Controlled Trial of Endoscopic Variceal Ligation Versus Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06594744 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

A Randomized Controlled Trial of Endoscopic Variceal Ligation Versus Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma

TypeinterventionalSponsorTaipei Veterans General Hospital, TaiwanRan2024 to 2030Enrolled120ConditionsHepatocellular Carcinoma (HCC), Esophageal VaricesArmsEndoscopic variceal ligation, Carvedilol
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. [Chinese expert consensus on the use of standardized second-line drugs for primary hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Sabrina SidaliUniversité de Paris, Assistance-Publique Hôpitaux de Paris, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Clichy, France.
Jean-Charles NaultCentre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, Team Functional Genomics of Solid Tumors, Equipe labellisée Ligue Nationale Contre le Cancer, Labex OncoImmunology, Paris, France.ORCID 0000-0002-4875-9353

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularHypertension, PortalLiver NeoplasmsHumans

Identifiers

PMID34997990
PMCPMC8830280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.